» Articles » PMID: 36301195

Racial and Ethnic Disparities in HIV Testing in People Who Use Drugs Admitted to a Tertiary Care Hospital

Overview
Date 2022 Oct 27
PMID 36301195
Authors
Affiliations
Soon will be listed here.
Abstract

Ending the HIV epidemic requires increased testing, diagnosis, and linkage to care. In the past 10 years, rates of HIV have increased among people with substance use disorder (SUD). HIV testing is recommended during hospitalization. Despite rising rates of infections and recommendations, HIV testing remains suboptimal. This study sought to detect differences in HIV testing by race and ethnicity in people who use drugs (PWUD) admitted to Tufts Medical Center (TuftsMC). This study is a retrospective review of hospitalized PWUD admitted from January 1, 2017 to December 31, 2020. PWUD were identified through toxicology results, medication prescribed for SUD, and nursing intake questions. The primary outcome of interest was whether an HIV test was ordered during hospitalization. The indicator of interest was race and ethnicity. Of 13,486 PWUD admitted to TuftsMC, only 10% had an HIV test ordered. Compared with White patients, Black patients [adjusted odds ratio (AOR): 0.69, 95% confidence interval (CI) (0.59-0.83)] and Hispanic patients [AOR: 0.68, 95% CI (0.55-0.84)] had decreased odds of receiving an HIV test. Our report is the first to show racial and ethnic differences in HIV testing ordering for hospitalized PWUD. Without access to harm reduction tools and expanded systems-based testing strategies, the HIV epidemic will continue and disproportionately impact minoritized communities.

Citing Articles

National HIV and HCV Screening Rates for Hospitalized People who Use Drugs Are Suboptimal and Heterogeneous Across 11 US Hospitals.

Westgard L, Sato T, Bradford W, Eaton E, Pilcher F, Hale A Open Forum Infect Dis. 2024; 11(5):ofae204.

PMID: 38746950 PMC: 11093397. DOI: 10.1093/ofid/ofae204.


Implementation of a bundle to improve HIV testing during hospitalization for people who inject drugs.

Grussing E, Pickard B, Khalid A, Smyth E, Childs V, Zubiago J Implement Res Pract. 2023; 4:26334895231203410.

PMID: 37936964 PMC: 10548809. DOI: 10.1177/26334895231203410.


Integrated Care Models: HIV and Substance Use.

Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S Curr HIV/AIDS Rep. 2023; 20(5):286-295.

PMID: 37698755 PMC: 11034717. DOI: 10.1007/s11904-023-00667-9.

References
1.
Gilbert L, Goddard-Eckrich D, Chang M, Hunt T, Wu E, Johnson K . Effectiveness of a Culturally Tailored HIV and Sexually Transmitted Infection Prevention Intervention for Black Women in Community Supervision Programs: A Randomized Clinical Trial. JAMA Netw Open. 2021; 4(4):e215226. PMC: 8035652. DOI: 10.1001/jamanetworkopen.2021.5226. View

2.
Mwachofi A, Fadul N, Dortche C, Collins C . Cost-effectiveness of HIV screening in emergency departments: a systematic review. AIDS Care. 2020; 33(10):1243-1254. DOI: 10.1080/09540121.2020.1817299. View

3.
DiNenno E, Delaney K, Pitasi M, MacGowan R, Miles G, Dailey A . HIV Testing Before and During the COVID-19 Pandemic - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022; 71(25):820-824. DOI: 10.15585/mmwr.mm7125a2. View

4.
Ciccarone D . The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021; 34(4):344-350. PMC: 8154745. DOI: 10.1097/YCO.0000000000000717. View

5.
Jones C . Levels of racism: a theoretic framework and a gardener's tale. Am J Public Health. 2000; 90(8):1212-5. PMC: 1446334. DOI: 10.2105/ajph.90.8.1212. View